<DOC>
	<DOCNO>NCT01064505</DOCNO>
	<brief_summary>This open-label , dose escalation , safety , tolerability pharmacokinetic study , active study drug ( QPI-1007 ) give patient participate . This study determine whether QPI-1007 safe inject eye . The study also reveal side effect drug long take body clear drug .</brief_summary>
	<brief_title>Safety Study Single IVT Injection QPI-1007 Chronic Optic Nerve Atrophy Recent Onset NAION Patients</brief_title>
	<detailed_description>Patients enrol accord one two set criterion designate Stratum I Stratum II . 1 . Stratum I enroll Optic Nerve Atrophy patient meet necessary criterion . Stratum I consist maximum 6 cohort cohort enroll 3 6 evaluable patient . Enrollment Stratum I close . 2 . Stratum II enroll patient diagnose acute Non Arteritic Anterior Ischemic Optic Neuropathy ( NAION ) within 28 day symptom onset meet necessary criterion . Stratum II consist maximum 3 cohort cohort enroll 10 evaluable patient . Enrollment Stratum II still open .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Optic Nerve Diseases</mesh_term>
	<mesh_term>Optic Neuropathy , Ischemic</mesh_term>
	<mesh_term>Optic Atrophy</mesh_term>
	<criteria>Key Stratum I ( Chronic Optic Nerve Atrophy ) `` Legally blind '' study eye result irreversible condition affect posterior segment eye . Clear ocular medium able undergo adequate pupil dilation . Visual acuity visual field nonstudy eye well equal study eye At least 21 year old . Key Stratum I ( Chronic Optic Nerve Atrophy ) For study eye : history IVT injection vitrectomy , vitreous hemorrhage , retinal detachment , active inflammatory condition ( e.g . conjunctivitis ) . For either eye : history uveitis . Enrollment close Stratum I . Key Stratum II ( Acute NAION ) Positive diagnosis NAION symptom onset within 28 day prior plan dose QPI1007 . Visual acuity study eye 20/40 light perception . Clear ocular medium able undergo adequate pupil dilation . At least 50 year old . Key Stratum II ( Acute NAION ) For study eye : Macular disease , retinopathy , eye disease limit visual acuity ; prior intraocular surgery ( Lasik ) cataract surgery within 3 month prior dose ; glaucoma laser surgery within 1 month prior dose ; pain aggravate eye movement ; history vitreous hemorrhage ; history retinal detachment ; active inflammatory condition ( e.g . conjunctivitis ) ; glaucoma ocular hypertension ; intraocular pressure &gt; 26 mmHg . For either eye : History optic neuritis ; history uveitis . Received treatment NAION prior dose . Any abnormality opinion investigator suggestive disease NAION study eye . Clinical evidence temporal arteritis . History collagen vascular disease inflammatory disease , history multiple sclerosis . Enrollment Stratum II still open .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Ocular Neuroprotection</keyword>
	<keyword>ocular neuroprotectant</keyword>
	<keyword>NAION</keyword>
	<keyword>NAAION</keyword>
	<keyword>Non-arteritic ischemic optic neuropathy</keyword>
	<keyword>Non-arteritic anterior ischemic optic neuropathy</keyword>
	<keyword>chronic optic nerve atrophy</keyword>
	<keyword>optic nerve atrophy</keyword>
	<keyword>retinal degeneration</keyword>
	<keyword>optic neuritis</keyword>
	<keyword>end stage glaucoma</keyword>
	<keyword>Leber 's hereditary optic neuropathy</keyword>
</DOC>